The Future

Egalet^® products have already been successfully tested in vitro and in vivo with a variety of active ingredients including peptides and unstable molecules. Clearly, the technology offers new possibilities in controlled release drug delivery for both well-known and new chemical entities. Accordingly, Egalet a/s continuously seeks new licensing partners that will enable us to further explore the growing market further for enhanced pharmaceutical formulations.

If you would like to know more about entering development cooperation with Egalet a/s please contact:

Anne-Marie Lademann, Director of Business Development, Patents & Licensing

or

Jan Quistgaard, President & CEO